查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1702013

2025 年至 2033 年癌症診斷市場報告（按產品、技術、應用、最終用戶和地區）

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2024年全球癌症診斷市場規模達2,079億美元。展望未來， IMARC Group預計到2033年市場規模將達到3,262億美元，2025-2033年期間的成長率（CAGR）為4.88%。人們對疾病早期發現的認知不斷提高、由於生活方式改變和遺傳傾向而導致的癌症患病率上升、以及診斷技術的進步以加強對患者的護理是推動市場發展的一些主要因素。

癌症診斷可以識別並確定個別癌症的存在、類型和階段。它包括一系列分析血液、組織和基因樣本的技術，例如磁振造影 (MRI)、X光和實驗室測試。它使醫療保健專業人員能夠準確地檢測和評估體內的癌症。它還使醫療保健提供者能夠根據疾病的具體特徵量身定做干涉措施，從而最佳化患者的治療結果。它有助於增強治療決策並制定個人化的治療策略。

目前，人們越來越傾向於採用非侵入性診斷方法，以最大限度地減少個人的不適和侵入性，這有助於市場的成長。除此之外，對經濟高效且準確的診斷技術的需求不斷成長，也促進了市場的成長。與此相符的是，人工智慧 (AI)、機器學習 (ML) 和資料分析在癌症診斷中的日益融合，以獲得更快、更準確的結果，正在推動市場的成長。除此之外，一些國家的管理機構和衛生部門正在組織活動，向全世界大眾傳播有關癌症及其診斷的認知。此外，個人化醫療需求的不斷成長以及全球醫療保健基礎設施的不斷改善，為市場帶來了積極的前景。

癌症診斷市場趨勢/促進因素：

癌症發生率上升

由於生活方式的改變、環境因素、人口老化和遺傳傾向等各種因素，癌症發生率有所上升。由於基因突變的累積和接觸潛在致癌物的時間延長，人們罹患癌症的幾率越來越大。此外，不良飲食習慣和缺乏體力活動等生活方式的改變也會增加罹患癌症的風險。除此之外，人們越來越傾向於早期發現以便有效治療癌症。此外，為了避免個人出現進一步的併發症，對準確及時的癌症診斷的需求不斷成長，這也促進了市場的成長。除此之外，醫療保健服務的日益普及也促進了市場的成長。

診斷技術的進步

製造商正在不斷改進其診斷技術，以提供更高的敏感性、特異性和可近性。與此相符的是，分子和基因檢測技術，例如下一代定序和液體活體組織切片，能夠檢測與不同類型癌症相關的特定生物標記。這些技術提供了對腫瘤特徵的洞察並允許客製化治療方法。除此之外，正子斷層掃描-電腦斷層掃描 (PET-CT) 和磁振造影 (MRI) 等影像方式的創新提供了更詳細和準確的腫瘤可視化，有助於診斷和分期。此外，技術的不斷進步提高了癌症診斷的精確度，這為市場前景帶來了積極的影響。

人們對早期發現疾病的認知不斷提高

消費者對早期癌症檢測重要性的認知不斷提高，促進了市場的成長。人們正在尋求定期篩檢和診斷測試來監測他們的健康狀況。此外，醫療保健提供者和組織正在組織許多活動，向公眾宣傳早期介入的好處，從而促進積極主動的健康尋求行為。除此之外，早期發現不僅可以改善治療效果，還可以減輕晚期癌症相關的整體醫療負擔。各國管理機構和醫療機構都在提供便利的篩檢項目，並強調及時診斷癌症的重要性。這些措施鼓勵人們定期進行癌症篩檢，對市場產生了正面影響。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球癌症診斷市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依產品

  • 耗材
    • 關鍵部分
      • 抗體
      • 試劑盒和試劑
      • 探針
      • 其他
  • 儀器
    • 關鍵部分
      • 病理學儀器
      • 成像儀器
      • 切片器械

第7章：市場區隔：依技術

  • 體外診斷試劑 (IVD) 測試
    • 關鍵部分
      • 聚合酶鍊式反應（PCR）
      • 原位雜合技術（ISH）
      • 免疫組織化學（IHC）
      • 下一代定序（NGS）
      • 微陣列
      • 流式細胞儀
      • 免疫測定
      • 其他
  • 影像學
    • 關鍵部分
      • 磁振造影（MRI）
      • 電腦斷層掃描（CT）
      • 正子斷層掃描（PET）
      • 乳房X光檢查
      • 超音波
  • 切片技術

第 8 章：市場區隔：按應用

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 黑色素瘤
  • 其他

第9章：市場區隔：依最終用戶

  • 醫院和診所
  • 診斷實驗室
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • GE HealthCare (General Electric Company)
    • Hologic Inc.
    • Illumina Inc.
    • Koninklijke Philips NV
    • Pfizer Inc.
    • Qiagen NV
    • Quest Diagnostics
    • Siemens Healthineers AG (Siemens AG)
    • Thermo Fisher Scientific Inc.
Product Code: SR112025A6322

The global cancer diagnostics market size reached USD 207.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 326.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.88% during 2025-2033. The growing awareness about early detection of disease, rising prevalence of cancer due to lifestyle changes and genetic predisposition, and advancements in diagnostics techniques to enhance patient care are some of the major factors propelling the market.

Cancer diagnostics identifies and determines the presence, type, and stage of cancer among individuals. It comprises a range of techniques and technologies, such as magnetic resonance imaging (MRI), X-rays, and laboratory tests, that analyze blood, tissue, and genetic samples. It allows healthcare professionals to accurately detect and assess cancerous growths within the body. It also enables healthcare providers to optimize patient outcomes by tailoring interventions to the specific characteristics of the disease. It assists in enhancing treatment decisions and developing personalized therapeutic strategies.

At present, the increasing preference for non-invasive diagnostic approaches that minimize discomfort and invasiveness among individuals is contributing to the growth of the market. Besides this, the rising demand for cost-effective and accurate diagnostics techniques is strengthening the market growth. In line with this, the increasing integration of artificial intelligence (AI), machine learning (ML), and data analytics in cancer diagnostics to enable quicker and more accurate results is propelling the growth of the market. Apart from this, governing agencies and healthcare authorities of several countries are organizing campaigns to spread awareness about cancer and its diagnostics among the masses worldwide. Furthermore, the growing demand for personalized medicines, along with the improving healthcare infrastructure around the world, is offering a positive market outlook.

Cancer Diagnostics Market Trends/Drivers:

Rising prevalence of cancer

There is a rise in the incidence of cancer due to various factors, such as lifestyle changes, environmental exposures, aging population, and genetic predisposition. People are increasingly suffering from cancer due to accumulated genetic mutations and longer exposure periods to potential carcinogens. In addition, lifestyle changes, such as poor diet and limited physical activity, is contributing to higher cancer risk. Apart from this, people are increasingly preferring early detection for effective treatment of cancer. Additionally, the rising demand for accurate and timely cancer diagnosis to avoid further complications among individuals is contributing to the growth of the market. Besides this, the increasing accessibility to healthcare services is bolstering the growth of the market.

Advancements in diagnostics techniques

Manufacturers are increasingly advancing their diagnostic technologies to offer greater sensitivity, specificity, and accessibility. In line with this, molecular and genetic testing techniques, such as next-generation sequencing and liquid biopsies, enable the detection of specific biomarkers associated with different types of cancer. These technologies provide insights into tumor characteristics and allow customized treatment approaches. Apart from this, innovations in imaging modalities, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), offer more detailed and accurate visualization of tumors that aid in diagnosis and staging. In addition, the continuous advancement in technologies enhances the precision of cancer diagnostics, which is offering a positive market outlook.

Growing awareness about early detection of diseases

Increasing consumer awareness about the importance of early cancer detection is bolstering the growth of the market. Individuals are seeking regular screenings and diagnostic tests to monitor their health conditions. Moreover, healthcare providers and organizations are organizing numerous campaigns to educate the public about the benefits of early intervention, thereby promoting proactive health-seeking behavior. Apart from this, early detection not only improves treatment outcomes but reduces the overall healthcare burden associated with advanced-stage cancer. Governing agencies and healthcare institutions of various countries are providing accessible screening programs and emphasizing the importance of timely cancer diagnosis. These initiatives encourage individuals to go for regular screening for cancer, which is positively influencing the market.

Cancer Diagnostics Industry Segmentation:

Breakup by Product:

  • Consumables
  • Antibodies
  • Kits and Reagents
  • Probes
  • Others
  • Instruments
  • Pathology-based Instruments
  • Imaging Instruments
  • Biopsy Instruments

Consumables comprise a wide range of products used in the process of cancer diagnostics. These include reagents, test kits, stains, and antibodies that are utilized in various diagnostic procedures, such as immunohistochemistry, molecular testing, and blood-based assays. In addition, consumables play a crucial role in facilitating accurate sample processing, analysis, and interpretation. The rising adoption of consumables due to the increasing demand for diagnostic testing in cancer care is bolstering the growth of the market.

Instruments refer to the equipment and devices employed to perform diagnostic tests and procedures. This category encompasses a diverse range of technologies, such as imaging equipment, laboratory equipment, and diagnostic platforms. Apart from this, there is a rise in the innovation of diagnostic instruments to improve the accuracy, speed, and efficiency of cancer diagnostics.

Breakup by Technology:

  • IVD Testing
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-generation Sequencing (NGS)
  • Microarrays
  • Flow Cytometry
  • Immunoassays
  • Others
  • Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound

Biopsy Technique

Imaging accounts for the majority of the market share

Imaging technologies involve the usage of advanced medical equipment to visualize internal structures and detect abnormalities within the body. Imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, and ultrasound, provide detailed images of tumors and their size, location, and potential metastases. These technologies aid in tumor detection, staging, and treatment monitoring. In line with this, they play a vital role in guiding medical decisions, enabling precise surgical interventions, and evaluating treatment responses.

Breakup by Application:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

Breast cancer represents the largest market share

Breast cancer diagnostics comprise a wide range of methods for the early detection, diagnosis, and monitoring of breast tumors. Mammography is a widely used imaging technique that aids in detecting abnormalities, such as masses or microcalcifications. Besides this, biopsy procedures, such as core needle and fine-needle biopsies, provide tissue samples for pathological analysis that determine the nature and stage of the tumor. Molecular tests assess specific biomarkers like HER2/neu and estrogen receptor status. In addition, advanced imaging methods, such as breast MRI and molecular breast imaging, offer enhanced visualization and characterization of lesions.

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others

Hospitals and clinics hold the biggest market share

Hospitals serve as comprehensive healthcare institutions that are equipped with advanced diagnostic equipment and expert medical personnel. They offer a wide range of cancer diagnostic services and provide comprehensive treatment planning based on diagnostic findings. On the other hand, clinics involve specialized cancer centers that cater to outpatient needs and often focus exclusively on cancer care. They offer diagnostics, such as mammograms and consultations, which makes it convenient for patients to receive timely evaluations. Both hospitals and clinics play pivotal roles in delivering accurate and efficient diagnostics for cancer patients.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest cancer diagnostics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the improved healthcare infrastructure. Apart from this, the rising focus on early detection of diseases among individuals is contributing to the growth of the market in the region. In line with this, the increasing awareness about cancer, along with favorable reimbursement policies, is propelling the growth of the market. Besides this, the presence of key diagnostic technology manufacturers, research institutions, and a strong network of healthcare facilities is bolstering the growth of the market in the North America region.

Competitive Landscape:

Major players are investing in research and development (R&D) activities to develop innovative diagnostic technologies. This involves exploring new biomarkers, improving imaging modalities, and enhancing the accuracy of molecular and genetic testing methods. In addition, diagnostic companies are continuously updating their existing technologies and platforms and incorporating artificial intelligence (AI) and machine learning (ML) algorithms for more accurate interpretation of diagnostic results. Apart from this, many companies are engaging in collaboration with research institutions, universities, and healthcare providers to gain expert knowledge and can access patient data for validation and improvement of diagnostic tools. Furthermore, key players are introducing new diagnostic products and services that focus on improved sensitivity, specificity, and ease of use.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • GE HealthCare (General Electric Company)
  • Hologic Inc.
  • Illumina Inc.
  • Koninklijke Philips N.V.
  • Pfizer Inc.
  • Qiagen N.V
  • Quest Diagnostics
  • Siemens Healthineers AG (Siemens AG)
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global cancer diagnostics market in 2024?
  • 2.What is the expected growth rate of the global cancer diagnostics market during 2025-2033?
  • 3.What are the key factors driving the global cancer diagnostics market?
  • 4.What has been the impact of COVID-19 on the global cancer diagnostics market?
  • 5.What is the breakup of the global cancer diagnostics market based on the technology?
  • 6.What is the breakup of the global cancer diagnostics market based on the application?
  • 7.What is the breakup of the global cancer diagnostics market based on the end user?
  • 8.What are the key regions in the global cancer diagnostics market?
  • 9.Who are the key players/companies in the global cancer diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Antibodies
      • 6.1.2.2 Kits and Reagents
      • 6.1.2.3 Probes
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Pathology-based Instruments
      • 6.2.2.2 Imaging Instruments
      • 6.2.2.3 Biopsy Instruments
    • 6.2.3 Market Forecast

7 Market Breakup by Technology

  • 7.1 IVD Testing
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction (PCR)
      • 7.1.2.2 In Situ Hybridization (ISH)
      • 7.1.2.3 Immunohistochemistry (IHC)
      • 7.1.2.4 Next-generation Sequencing (NGS)
      • 7.1.2.5 Microarrays
      • 7.1.2.6 Flow Cytometry
      • 7.1.2.7 Immunoassays
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Imaging
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Magnetic Resonance Imaging (MRI)
      • 7.2.2.2 Computed Tomography (CT)
      • 7.2.2.3 Positron Emission Tomography (PET)
      • 7.2.2.4 Mammography
      • 7.2.2.5 Ultrasound
    • 7.2.3 Market Forecast
  • 7.3 Biopsy Technique
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Lung Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Melanoma
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Becton Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bio-Rad Laboratories Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GE HealthCare (General Electric Company)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Koninklijke Philips N.V.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Qiagen N.V
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Quest Diagnostics
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Siemens Healthineers AG (Siemens AG)
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Thermo Fisher Scientific Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Diagnostics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cancer Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Cancer Diagnostics Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Cancer Diagnostics Market: Breakup by Technology (in %), 2024
  • Figure 6: Global: Cancer Diagnostics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Cancer Diagnostics Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Cancer Diagnostics Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Cancer Diagnostics (Consumables) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Cancer Diagnostics (Consumables) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Cancer Diagnostics (Instruments) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Cancer Diagnostics (Instruments) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Cancer Diagnostics (IVD Testing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Cancer Diagnostics (IVD Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Cancer Diagnostics (Imaging) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Cancer Diagnostics (Imaging) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Cancer Diagnostics (Biopsy Technique) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Cancer Diagnostics (Biopsy Technique) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Cancer Diagnostics (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Cancer Diagnostics (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Cancer Diagnostics (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Cancer Diagnostics (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Cancer Diagnostics (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Cancer Diagnostics (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Cancer Diagnostics (Melanoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Cancer Diagnostics (Melanoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Cancer Diagnostics (Other Cancers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Cancer Diagnostics (Other Cancers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Cancer Diagnostics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Cancer Diagnostics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Cancer Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Cancer Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Cancer Diagnostics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Cancer Diagnostics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: North America: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: North America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: United States: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: United States: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Canada: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Canada: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Asia-Pacific: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Asia-Pacific: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: China: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: China: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Japan: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Japan: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: India: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: India: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: South Korea: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: South Korea: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Australia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Australia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Indonesia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Indonesia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Europe: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Europe: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Germany: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Germany: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: France: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: France: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: United Kingdom: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: United Kingdom: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Italy: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Italy: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Spain: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Spain: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Russia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Russia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Latin America: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Latin America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Brazil: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Brazil: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Mexico: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Mexico: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Middle East and Africa: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Middle East and Africa: Cancer Diagnostics Market: Breakup by Country (in %), 2024
  • Figure 83: Middle East and Africa: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Global: Cancer Diagnostics Industry: SWOT Analysis
  • Figure 85: Global: Cancer Diagnostics Industry: Value Chain Analysis
  • Figure 86: Global: Cancer Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Diagnostics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Cancer Diagnostics Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Cancer Diagnostics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 4: Global: Cancer Diagnostics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Cancer Diagnostics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Cancer Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Cancer Diagnostics Market: Competitive Structure
  • Table 8: Global: Cancer Diagnostics Market: Key Players